Gene Therapy Sample Clauses

Gene Therapy. The electronic versions of (a) the most recent print edition of Gene Therapy; and (b) all previous print editions of Gene Therapy that were first published within the previous four (4) years, from the later of the Commencement Date or the most recent of any subsequent Renewal Date (both as defined herein), but in any event all editions first published since the Commencement Date, in each case as available for access on the Internet at the URL xxxx://xxx.xxxxxx.xxx/gt together with any additional material that the Licensor makes available to the Licensee.
AutoNDA by SimpleDocs
Gene Therapy. Students will learn the history of gene therapy and the principal concepts behind gene therapy applications. We will cover the early gene therapy failures and the important lessons learned from these studies, which led to modified strategies based upon improved understanding of genetic components and how this knowledge led to successful translation for the treatment of human diseases like genetic disorders and cancer. Genome Editing: Students will be introduced to genome editing technologies, including transcription activator-like effector nucleases (TALENs), zinc-finger nucleases (ZFNs) and clustered regularly interspaced short palindromic repeats (CRISPR)-associated nuclease Cas9. Bioinformatics: Students will get an overview of bioinformatics resources for analysis of protein sequences. They will be introduced to immunomic and infectivity databases and learn how to deal with immunogenicity analysis. Assessment method Emerging Viral Infections: Discovery and Intervention Strategies Organization: Hannover Medical School Teaching unit coordinator: Teaching unit coordinator: Xxxxxx XXXXXXXXX, Xxxx XXXXXXXXXXX Teaching unit outline Topics addressed
Gene Therapy. 4 1.16 Genentech Knowhow........................................................5 1.17 Genentech Manufacturing Knowhow..........................................5 1.18 Genentech Patent Rights..................................................5 1.19 IND......................................................................6 1.20
Gene Therapy. During the term of the Program, Millennium and Lilly agree to discuss collaborations within the Field and the area of Oncology concerning candidates for gene therapy arising from the Program. The initial opportunity to begin such discussions concerning gene therapy shall arise when a gene that is appropriate for use in gene therapy is discovered in the course of the Millennium Research Program or a [**] and is brought to the attention of the Joint Management Team. When this occurs, the parties shall have a period of [**] in which to decide whether to begin good faith negotiations with each other concerning a potential gene therapy collaboration on such a gene. If the parties decide to Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. collaborate on a gene therapy project, the terms of such collaboration shall be governed by the terms and conditions of a separate agreement. If, either (a) a gene described in the preceding paragraph has a potential application only outside of Oncology, (b) the parties choose not to negotiate with each other concerning a collaboration within Oncology, or (c) the parties cannot agree to the terms of a collaboration within Oncology, then each party shall have a co-exclusive right to make, use and sell a Gene Therapy Drug embodying such a gene for all gene therapy applications, both within the Field and outside the Field, within the Territory. Each party shall be entitled to sublicense the co-exclusive rights to make, use and sell each Gene Therapy Drug embodying such gene to one (1) sublicensee per country. Any further licensing of the Gene Therapy Drug embodying such gene shall require the [**]. Each party shall pay the other party a [**] on its Net Sales of the Gene Therapy Product within the Territory. All royalty payments shall be made subject to the provisions of Article VIII of this Agreement. In the event that the total royalty burden of any Gene Therapy Product sold by a party is greater than [**] of the Net Sales of the Gene Therapy Product in the Territory (inclusive of the [**] paid under the terms of this Section 5.3), then that party's royalty payable to the other party shall [**] of the excess over [**] paid by that party; provided, however, the royalty payment to the other party shall not fall below [**] of Net Sales of the Gene Therapy Product in the Territory. Nothing within this Section 5.3 grants Millennium any rights to Candidate Gene...
Gene Therapy. Gene therapy remains the most promising treatment approach for most NCLs, including the transmembrane protein-deficient forms. A relatively large number of cells will need to be transduced in transmembrane protein-deficient NCLs compared to those that lack lysosomal enzymes, as the neighbouring affected cells cannot rely on cross correction from transduced cells (Xxxxxxxx et al., 2015; X.
Gene Therapy. Gene therapy or gene-based therapies are not covered.

Related to Gene Therapy

  • Speech Therapy This plan covers speech therapy services when provided by a qualified licensed • loss of speech or communication function; or • impairment as a result of an acute illness or injury, or an acute exacerbation of a chronic disease. Speech therapy services must relate to: • performing basic functional communication; or • assessing or treating swallowing dysfunction. See Autism Services when speech therapy services are rendered as part of the treatment of autism spectrum disorder. The amount you pay and any benefit limit will be the same whether the services are provided for habilitative or rehabilitative purposes.

  • Diagnostic procedures to aid the Provider in determining required dental treatment.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Radiation Therapy/Chemotherapy Services This plan covers chemotherapy and radiation services. This plan covers respiratory therapy services. When respiratory services are provided in your home, as part of a home care program, durable medical equipment, supplies, and oxygen are covered as a durable medical equipment service.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Diagnostic Services All necessary procedures to assist the dentist in evaluating the existing conditions to determine the required dental treatment, including: Oral examinations Consultations

  • Manufacturing Technology Transfer Upon AbbVie’s written request with respect to a given Collaboration CAR-T Product and Licensed Product, Caribou shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party Provider) of all Materials and Know-How Controlled by Caribou relating to the then-current process for the Manufacture of such Collaboration CAR-T Product and any corresponding Licensed Products (each, a “Manufacturing Process”). Caribou shall provide, shall cause its Affiliates to provide, and shall use Commercially Reasonable Efforts to assist AbbVie in causing all Third Party Providers to provide, all reasonable assistance requested by AbbVie to enable AbbVie (or its Affiliate or designated Third Party Provider, as applicable) to implement each Manufacturing Process at the facilities designated by AbbVie. If requested by AbbVie, such assistance shall include facilitating the entering into of agreements with applicable Third Party suppliers relating to such Collaboration CAR-T Product and any corresponding Licensed Products. Without limitation of the foregoing, in connection with the Manufacturing Process and related transfer: (a) Caribou shall, and shall cause its Affiliates to, make available to AbbVie (or its Affiliate or designated Third Party Provider, as applicable), and shall use Commercially Reasonable Efforts to assist AbbVie in causing all Third Party Providers to make available to AbbVie, from time to time as AbbVie may request, all Materials and Manufacturing-related Know-How Controlled by Caribou relating to each Manufacturing Process, including methods, reagents and processes and testing/characterization Know-How, and all documentation constituting material support, performance advice, shop practice, standard operating procedures, specifications as to Materials to be used, and control methods, that are necessary or reasonably useful to enable AbbVie (or its Affiliate or designated Third Party manufacturer, as applicable) to use and practice such Manufacturing Process; (b) Caribou shall cause all appropriate employees and representatives of Caribou and its Affiliates, and shall use Commercially Reasonable Efforts to assist AbbVie in causing all appropriate employees and representatives of Third Party Providers, to meet with employees or representatives of AbbVie (or its Affiliate or designated Third Party Provider, as applicable) at the applicable manufacturing facility at mutually convenient times to assist with the working up and use of each Manufacturing Process and with the training of the personnel of AbbVie (or its Affiliate or designated Third Party Provider, as applicable) to the extent necessary or reasonably useful to enable AbbVie (or its Affiliate or designated Third Party Provider, as applicable) to use and practice such Manufacturing Process; (c) Without limiting the generality of this Section 4.4.2, Caribou shall cause all appropriate analytical and quality control laboratory employees and representatives of Caribou and its Affiliates, and shall use Commercially Reasonable Efforts to assist AbbVie in causing all appropriate analytical and quality control laboratory employees and representatives of Third Party Providers, to meet with employees or representatives of AbbVie (or its Affiliate or designated Third Party Provider, as applicable) at the applicable manufacturing facility and make available all necessary equipment, at mutually convenient times, to support and execute the provision of all applicable analytical methods and the validation thereof (including all applicable Know-How, Information and Materials Controlled by Caribou, and sufficient supplies of all primary and other reference standards); (d) Caribou shall, and shall cause its Affiliates to, take such steps, and shall use Commercially Reasonable Efforts to assist AbbVie in causing Third Party Providers take such steps, as are necessary or reasonably useful to assist AbbVie (or its Affiliate or designated Third Party Provider, as applicable) in obtaining any necessary licenses, permits or approvals from Regulatory Authorities with respect to the Manufacture of the applicable Collaboration CAR-T Products and corresponding Licensed Products at the applicable facilities; and (e) Caribou shall, and shall cause its Affiliates to, provide, and shall use Commercially Reasonable Efforts to assist AbbVie in causing Third Party Providers to provide, such other assistance as AbbVie (or its Affiliate or designated Third Party Provider, as applicable) may reasonably request to enable AbbVie (or its Affiliate or designated Third Party Provider, as applicable) to use and practice each Manufacturing Process and otherwise to Manufacture the applicable Collaboration CAR-T Products and corresponding Licensed Products.

  • Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!